Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, 07065, USA.
Waters Corporation, Beverly, Massachusetts, 01915, USA.
Pharm Res. 2020 May 27;37(6):107. doi: 10.1007/s11095-020-02823-x.
Desorption electrospray ionization mass spectrometry imaging (DESI-MSI) coupled with gas-phase ion mobility spectrometry was used to characterize the drug distribution in polymeric implants before and after exposure to accelerated in vitro release (IVR) media. DESI-MSI provides definitive chemical identification and localization of formulation components, including 2D chemical mapping of individual components with essentially no sample preparation.
Polymeric implants containing 40% (w/w) entecavir and poly(D,L-lactide) (PLA) were prepared and then exposed to either acidified PBS (pH 2.5) or MeOH:HO (50:50, v/v) medias during a 7-day IVR test using continuous flow-through (CFT) cell dissolution. The amount of drug released from the polymer matrix during the 7-day IVR test was monitored by online-ultraviolet spectroscopy (UV) and HPLC-UV. After that period, intact implants and radial sections of implants were analyzed by DESI-MSI with ion mobility spectrometry. The active ingredient along with impurities and contaminants were used to generate chemical maps before and after exposure to the release medias.
Bi-phasic release profiles were observed for implants during IVR release using both medias. During the second phase of release, implants exposed to PBS, pH 2.5, released the entecavir faster than the implants exposed to MeOH:HO (50:50, v/v). Radial images of the polymer interior show that entecavir is localized along the central core of the implant after exposure to MeOH:HO (50:50, v/v) and that the drug is more uniformly distributed throughout the implant after exposure to acidified PBS (pH 2.5).
DESI-MSI coupled with ion mobility analysis produced chemical images of the drug distribution on the exterior and interior of cylindrical polymeric implants before and after exposure to various release medias. These results demonstrated the utility of this technique for rapid characterization of drug and impurity/degradant distribution within polymeric implants with direct implications for formulation development as well as analytical method development activities for various solid parenteral and oral dosage forms. These results are especially meaningful since samples were analyzed with essentially no preparative procedures.
采用解吸电喷雾电离质谱成像(DESI-MSI)结合气相离子淌度谱法,对暴露于加速体外释放(IVR)介质前后的聚合物植入物中的药物分布进行了表征。DESI-MSI 可提供配方成分的明确化学鉴定和定位,包括对单个成分进行二维化学映射,且基本无需样品制备。
制备含有 40%(w/w)恩替卡韦和聚(D,L-丙交酯)(PLA)的聚合物植入物,然后将其分别暴露于酸化 PBS(pH 2.5)或 MeOH:HO(50:50,v/v)介质中,在连续流动(CFT)细胞溶解中进行为期 7 天的 IVR 测试。通过在线紫外光谱(UV)和 HPLC-UV 监测 7 天 IVR 测试期间药物从聚合物基质中的释放量。在此期间,使用 DESI-MSI 结合离子淌度谱对完整植入物和植入物的径向切片进行分析。使用活性成分及杂质和污染物生成暴露于释放介质前后的化学图谱。
两种介质在 IVR 释放过程中均观察到植入物的双相释放曲线。在释放的第二阶段,暴露于 PBS、pH 2.5 的植入物比暴露于 MeOH:HO(50:50,v/v)的植入物释放恩替卡韦更快。聚合物内部的径向图像显示,暴露于 MeOH:HO(50:50,v/v)后,恩替卡韦定位于植入物的中心核,暴露于酸化 PBS(pH 2.5)后,药物在植入物中分布更均匀。
DESI-MSI 结合离子淌度分析在暴露于各种释放介质前后,对圆柱形聚合物植入物的外部和内部的药物分布进行了化学成像。这些结果证明了该技术用于快速表征药物和杂质/降解物在聚合物植入物中的分布的实用性,这对制剂开发以及各种固体制剂和口服剂型的分析方法开发活动具有直接影响。这些结果意义重大,因为基本上无需制备程序即可对样品进行分析。